INDIANAPOLIS (Oct. 3, 2025) – Indiana Right to Life President and Chief Executive Officer Mike Fichter issued this statement today regarding the U.S. Food and Drug Administration’s approval of a generic version of mifepristone.
“The FDA approval of a generic abortion drug will fuel illegal trafficking of abortion drugs into Indiana.
“The generic version will make abortion pills cheaper by pennies to the dollar, making it easier for anyone to access, including abusive men willing to pay for cheap pills to end a woman or young girl’s pregnancy.
“We can also expect abortion drug complications to rise in Indiana. In the first three months of 2025 alone, the Indiana Department of Health noted nine reported abortion complications in Indiana involving abortion drugs. In 2024, there were 18 reported abortion complications. These reported complications are likely a very small percentage of the total complications actually occurring.
“It cannot be overlooked that the approval of a generic abortion drug is simply making the killing of an unborn child cheaper than at any other time in American history. It is difficult to fathom how this approval happened under a Trump administration that has indicated it is looking into safety concerns and protocols for abortion drugs.”
###
Media Contact: media@protectinglife.com
Recent Comments